South Carolina Retina Institute (SCRI) may, for certain patient eye conditions, administer XIPERE® – a revolutionary therapeutic eye treatment that received FDA approval in October 2021.
Breakthrough Therapies for Geographic Atrophy Offer Patients Hope at SCRI
In the pursuit of providing state-of-the-art care for patients dealing with age-related macular degeneration (AMD) and geographic atrophy (GA), South Carolina Retina Institute (SCRI) is pleased to introduce
Advanced Treatment for Wet AMD, Diabetic Retinopathy, and DME at South Carolina Retina Institute
Age-related macular degeneration (AMD) poses a significant threat to vision, impacting the lives of many individuals. At South Carolina Retina Institute (SCRI), we are committed to staying at the forefront of